Medication info

Valtriol Tablet 5/80/10 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Kyungdong Pharm Co., Ltd.
Appearance
Yellow, biconvex, film-coated tablet in a round shape
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202006708 · Approved 2020.09.29 · Insurance code 648104570

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended that the tablet be taken at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking the amlodipine/valsartan combination together with rosuvastatin as separate products, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Kyungdong Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential Hypertension
  • Primary Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia
  • Mixed Dyslipidemia
  • Homozygous Familial Hypercholesterolemia
  • Hypercholesterolemia
  • Primary Atypical Dyslipoproteinemia
  • Elevated High-Sensitivity C-Reactive Protein
  • Hypertension
  • Low HDL-Cholesterol Level
  • Smoking
  • Family History of Early Coronary Artery Disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure cannot be controlled adequately with either amlodipine or valsartan alone. Amlodipine and valsartan lower blood pressure, thereby reducing cardiovascular strain. Additionally, rosuvastatin is used as an adjunct for patients with hypercholesterolemia or dyslipidemia that cannot be controlled by diet and exercise, lowering blood cholesterol levels and slowing the progression of arteriosclerosis. Rosuvastatin is effective for familial hypercholesterolemia and atypical dyslipoproteinemia, helping to reduce cardiovascular disease risk. This medication is specifically used for patients who have both hypertension and hyperlipidemia, improving blood pressure and cholesterol control for cardiovascular disease prevention.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended that the tablet be taken at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking the amlodipine/valsartan combination together with rosuvastatin as separate products, switching to this medicine (a combination product containing the same amount of each active ingredient) may be considered for convenience. ▷ Amlodipine/valsartan combination Before starting the amlodipine/valsartan combination, it is recommended that the dose of the individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or to patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with hypersensitivity to this medication's components, or in women who are pregnant or nursing, or in patients with severe liver or kidney dysfunction. Patients with sodium or fluid depletion, hyperkalemia, renal artery stenosis, recent kidney transplant recipients, etc., should use this medication with special caution. In patients with heart failure, post-myocardial infarction patients, aortic stenosis, or severe myasthenia gravis, this medication should be used cautiously, and if symptoms of angioedema occur, it should be discontinued immediately. This medication can cause serious muscle-related side effects such as myalgia, myopathy, and, rarely, rhabdomyolysis, so patients should immediately notify their healthcare professional if they experience muscle pain or weakness. Caution is required as dizziness or fatigue may occur when driving or operating machinery. This medication may interact with other medications, so patients must inform their healthcare provider of any other medications they are taking. Pregnant or nursing women should not take this medication, and women planning to become pregnant should use appropriate contraceptive methods. It is not recommended for children or adolescents under 18, as safety and efficacy have not been established. When administering to the elderly, dosage adjustments or careful monitoring may be needed, and patient conditions should be closely observed. Regular liver function tests and blood tests should be conducted during the use of this medication to check for unusual reactions. In case of overdose, severe hypotension or heart function impairment may occur, requiring immediate medical attention.

Side effects

Dizziness, sensory disturbance, chest discomfort, chills, ALT increase, AST increase, weight gain, upper respiratory infection, myalgia, palpitations, ventricular extrasystoles, diarrhea, duodenitis, gastritis, dyspnea, blepharospasm, eyelid swelling, hypertriglyceridemia, benign prostatic hyperplasia, nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, drowsiness, orthostatic dizziness, paresthesia, vertigo, tinnitus, tachycardia, chest palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, nausea, abdominal pain, constipation, dry mouth, rash, erythema, sweating, itching, joint swelling, low back pain, arthritis, muscle cramps, lethargy, frequent urination, polyuria, erectile dysfunction, edema, periorbital edema, facial edema, peripheral edema, fatigue, flushing, asthenia, facial flushing, chest pain, pain, nocturia, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, thrombocytopenia, leukopenia, allergic reactions, hyperglycemia, insomnia, mood changes, tremor, taste disturbance, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, myocardial infarction, vasculitis, rhinitis, vomiting, dyspepsia, pancreatitis, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reactions, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, urinary disturbance, gynecomastia, malaise, weight loss, serum sickness, elevated serum potassium, vasculitis, elevated liver function tests, vesicular dermatitis, renal failure, kidney damage, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, viral infection, intestinal vascular edema, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, thrombocytopenia, jaundice, increased transaminases, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, visual impairment, retinal detachment, vitreous detachment, skin tumor, herpes zoster, herniated disc, lacerations, elevated blood creatinine, increased blood pressure, worsening hypertension, neck/shoulder pain, leg fractures, toe fractures, spinal fractures, fractures, osteomyelitis, skin infections, dermatitis unspecifed, localized skin reactions, palpitations, second-degree atrioventricular block, worsening angina, auditory disturbances, vestibular inflammation, overactive bladder, carpal tunnel syndrome, facial flushing, neural hyperexcitability, sensory impairment, Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature to preserve its effectiveness for a long time.

Appearance and packaging

Appearance

Yellow, biconvex, film-coated tablet in a round shape

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.